BVI announced that its FINEVISION HP (hydrophobic) Trifocal IOL has been successfully implanted during the first U.S.-based procedures across the country.
This news follows mere months after the FDA granted approval for the intraocular lens (IOL).
How exciting! Let’s start with a debrief on this lens.
The FINEVISION HP Trifocal IOL is the latest addition in BVI’s lineup of FINEVISION HP IOLs, featuring a proprietary diffractive trifocal IOL optic.
What makes these hydrophobic, diffractive trifocal IOLs unique: Their ability to provide continuous vision across distance, intermediate, and near focal points (without sacrificing near and distance vision acuities).
And the FINEVISION HP Trifocal IOL specifically?
Granted FDA approval in October 2025, this presbyopia-correcting lens features a GFY hydrophobic raw material optimized to boost long-term optical clarity. See here for our rundown.
Notably, the lens is built to:
- Offer optimized near vision (with the highest energy split allocated) and a high add power of 3.5 diopters (D)
- Enable an optimized range of vision, with two complementary add powers of 3.5 D and 1.75 D
Click here for data supporting its clinical demonstration of strong contrast sensitivity and stable visual performance across all lighting conditions—with enhanced near vision in dim light and a smooth, continuous range of vision from far to near.
Tell me about its lens technology design.
The FINEVISION HP also features a proprietary POD (double C-loop) haptic platform that enables rotational stability, good centration, and predictable behavior in the capsular bag.
Additionally: It utilizes BVI’s CoPODize technology, which manages the risk for halos and glare when transitioning to mesopic conditions.
- Check out its product brochure.
Alrighty, now to these first implantations.
The first real-world clinical cases were performed by five cataract and refractive surgeons—members of BVI’s U.S. Surgical Leadership Council—at surgical centers around the U.S.
Among the surgeons:
- Nicole Fram, MD, in Beverly Hills, California
- Nathan Radcliffe, MD, in Bronx, New York
- Vance Thompson, MD, in Sioux Falls, South Dakota
- George O. Waring, IV, MD, in Ladson, South Carolina
- Robert J. Weinstock, MD, in Largo, Florida
What do we know about each clinical case?
Aside from the name of the performing surgeon and their respective location? Not much.
However: According to reporting from Galveston County’s The Daily News, Dr. Waring performed the first implantation of the lens last week at the Waring Vision Institute in Mount Pleasant, South Carolina, where he serves as founder and medical director.
Dr. Waring referred to the procedure as an exciting moment for both surgeons and patients.
- “The availability of the BVI FineVision HP Trifocal IOL in the United States allows us to offer an innovative, clinically proven technology that has the potential to significantly enhance visual outcomes and patient satisfaction,” he shared with the local news outlet.
So … when can we expect a broader, nationwide use of this lens?
BVI’s Andy Chang, chief commercial officer, stated that the company is planning to expand access across the U.S. throughout 2026.